Bank of America Securities Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)

In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Hold rating on Idexx Laboratories, with a price target of $790.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Ryskin covers the Healthcare sector, focusing on stocks such as Zoetis, Bruker, and Idexx Laboratories. According to TipRanks, Ryskin has an average return of 1.1% and a 47.33% success rate on recommended stocks.

In addition to Bank of America Securities, Idexx Laboratories also received a Hold from TipRanks – xAI’s xAi Medical – Diagnostics and Research in a report issued on March 26. However, on April 6, William Blair maintained a Buy rating on Idexx Laboratories (NASDAQ: IDXX).

Based on Idexx Laboratories’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.09 billion and a net profit of $248.19 million. In comparison, last year the company earned a revenue of $954.29 million and had a net profit of $216.15 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IDXX in relation to earlier this year. Last month, Nimrata Hunt, the EVP of IDXX sold 1,758.00 shares for a total of $1,115,574.06.